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Abstract
Background: Obesity and asthma have reached epidemic proportions in the US. Their concurrent rise over the last 30 
years suggests that they may be connected. Numerous observational studies support a temporally-correct, dose-
response relationship between body mass index (BMI) and incident asthma. Weight loss, either induced by surgery or 
caloric restriction, has been reported to improve asthma symptoms and lung function. Due to methodological 
shortcomings of previous studies, however, well-controlled trials are needed to investigate the efficacy of weight loss 
strategies to improve asthma control in obese individuals.
Methods/Design: BE WELL is a 2-arm parallel randomized clinical trial (RCT) of the efficacy of an evidence-based, 
comprehensive, behavioral weight loss intervention, focusing on diet, physical activity, and behavioral therapy, as 
adjunct therapy to usual care in the management of asthma in obese adults. Trial participants (n = 324) are patients 
aged 18 to 70 years who have suboptimally controlled, persistent asthma, BMI between 30.0 and 44.9 kg/m2, and who 
do not have serious comorbidities (e.g., diabetes, heart disease, stroke). The 12-month weight loss intervention to be 
studied is based on the principles of the highly successful Diabetes Prevention Program lifestyle intervention. 
Intervention participants will attend 13 weekly group sessions over a four-month period, followed by two monthly 
individual sessions, and will then receive individualized counseling primarily by phone, at least bi-monthly, for the 
remainder of the intervention. Follow-up assessment will occur at six and 12 months. The primary outcome variable is 
the overall score on the Juniper Asthma Control Questionnaire measured at 12 months. Secondary outcomes include 
lung function, asthma-specific and general quality of life, asthma medication use, asthma-related and total health care 
utilization. Potential mediators (e.g., weight loss and change in physical activity level and nutrient intake) and 
moderators (e.g., socio-demographic characteristics and comorbidities) of the intervention effects also will be 
examined.
Discussion: This RCT holds considerable potential for illuminating the nature of the obesity-asthma relationship and 
advancing current guidelines for treating obese adults with asthma, which may lead to reduced morbidity and 
mortality related to the comorbidity of the two disorders.
Trial registration: NCT00901095
Background
Obesity has been increasingly linked to asthma. Over the
last 30 years there has been a rapid, concurrent increase
in the prevalence of both chronic diseases in the U.S. and
other westernized countries [1,2]. A growing number of
prospective studies support a temporally correct, dose-
response relationship between body mass index (BMI)
and incident asthma in adults and children of multiple
nationalities and racial/ethnic groups [3-5]. Obesity also
has been shown to alter prevalent asthma towards a more
difficult-to-control phenotype [6-11]. Some evidence
suggests that selected manifestations of the obesity-
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asthma relationship may be stronger in females [12-15].
Animal studies support a causal link between the two dis-
orders [16-18], and several mechanisms have been postu-
lated [5,19-21]. However, elucidating the exact nature of
the obesity-asthma association in humans remains an
area of active research [20].
The National Asthma Education and Prevention Pro-
gram Expert Panel Report 3 identified obesity as a signifi-
cant comorbidity and recommended that treatment of
obesity be considered in obese adults with asthma [22].
However, this recommendation was, in the Panel's evalu-
ation, based on limited data. The evidence available to
date suggests that weight loss, induced by surgery or
caloric restriction, is associated with improved asthma
symptoms, lung function, medication usage, and quality
of life in obese adults with asthma [23-26]. Much of this
research, however, suffers from notable methodological
inadequacies, which include lack of randomization, small
sample size, and short duration, among others. In addi-
tion, neither surgery nor caloric restriction alone is the
recommended first-line therapy for weight loss; the latter
emphasizes a comprehensive approach to lifestyle
change, focusing on diet, physical activity, and behavioral
self-management [27]. Further research is needed.
Aims
The BE WELL (Breathe Easier through Weight Loss Life-
style) intervention trial was designed to address the gap
in knowledge of whether weight loss improves asthma
control. It aims to evaluate the efficacy of an evidence-
based, comprehensive weight loss lifestyle intervention as
adjunct therapy to usual care in the management of
asthma in obese adults. The primary hypothesis is that
compared with participants in the usual care (UC) arm,
those in the weight loss intervention (WL) arm will
achieve greater improvement in asthma control, as mea-
sured by a validated composite measure, the Juniper
Asthma Control Questionnaire (ACQ) [28], at 12 months
follow-up. Secondary aims include comparing the WL
and UC arms on changes in ACQ scores at six months
and in lung function, asthma-specific quality of life
(QoL), asthma medication use, and asthma-related health
care utilization (HCU) at six and 12 months. Potential
mediators (e.g. weight loss and change in physical activity
level and diet composition) and moderators (e.g., socio-
demographic characteristics and comorbidities) of the
intervention effects will be explored.
Methods/Design
Study Design
BE WELL is a two-arm randomized controlled clinical
trial (RCT) in which obese patients ages 18-70 years with
suboptimally controlled, persistent asthma (n = 324) will
be equally randomized to the WL or UC arm. All proce-
dures and materials were approved by the Kaiser Founda-
tion Research Institute's Institutional Review Board.
Eligibility Criteria
Participants will be recruited from multiple medical cen-
ters of Kaiser Permanente in Northern California
(KPNC). Patients ages 18-70 years who are obese and
have suboptimally controlled, persistent asthma will be
eligible to participate. Table 1 enumerates the inclusion
and exclusion criteria. Exclusion criteria were designed to
ensure each participant's ability and safety to complete
the study requirements, minimize error associated with
primary outcome, and prevent possible missing data.
Individuals of both genders and any racial or ethnic back-
ground who speak English, meet the inclusion criteria,
and have no exclusion criteria will be eligible. Based on
the demographics of obese asthma patients at the
selected KPNC sites, the gender and ethnic distributions
of the target enrollment population are expected to con-
sist of 67% women, 57% White, 27% Black, 7% Hispanic/
Latino, and 9% Asian/Pacific Islander.
Recruitment and Screening Process
The target sample size for BE WELL is 324, to be
recruited in five sequential cohorts. Recruitment for each
cohort will begin by querying KPNC's electronic asthma
registry to identify obese adult patients who are likely to
have suboptimally controlled, persistent asthma based on
them past ER visits, hospitalizations, and/or medication
dispensing records. These patients will be reviewed by
their primary care provider (PCP) to determine whether
their participation in the study is medically appropriate
and safe. Patients for whom PCP approval is obtained will
be invited by mail to participate in the study and be asked
to complete, either online or by phone, a brief eligibility
screening questionnaire pertaining primarily to major
exclusions that patients can reliably answer on their own
(e.g., pregnancy, plans to move, active cancer). Patients
who pass the initial screen will be scheduled for a formal
in-person eligibility determination visit (BV1) and, if eli-
gible, a second visit (BV2) to complete baseline data col-
lection prior to randomization.
BV1 will occur no more than four months after the ini-
tial screen, and no more than two months prior to BV2.
Written informed consent will be obtained, followed by
completion of additional eligibility questionnaires,
including screening for angina, peripheral vascular dis-
ease (PVD), and severe depression. Height and weight
w i l l  b e  m e a s u r e d  a n d  B M I  c a l c u l a t e d .  P a t i e n t s  w h o s e
BMI is in the eligibility range between 30.0-44.9 kg/m2
will have spirometry performed before and after adminis-
tration of a short-acting beta agonist to determine revers-
ibility of airway obstruction. Patients with very poor lung
function (pre-bronchodilator forced expiratory volume inMa et al. BMC Pulmonary Medicine 2010, 10:16
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one second [FEV1]<40% of predicted or post-bronchodi-
lator FEV1<50% of predicted) or who have possible
angina, PVD, or severe depression will be referred to a
study physician and their PCP for evaluation and may
only continue in the study with explicit physician authori-
zation. Participants who prove fully eligible will be given
instructions, a two-week asthma diary form, and a three-
day food record form to be completed and returned at
BV2.
BV2 will occur at least two weeks after BV1 to allow
time for participants to complete the asthma diary and
food record. Also, BV2 will occur no more than four
weeks prior to the start of the intervention. It will involve
review of the patient's two-week asthma diary and three-
day food record, completion of the baseline question-
naire, measurement of weight, waist circumference, hip
circumference, blood pressure, and pre-bronchodilator
spirometry.
Randomization and Blinding
Following BV2, participants will be randomized in a 1:1
ratio to the WL or UC arm. By applying a balance algo-
rithm that originated in cluster randomized trials [29], BE
WELL randomization will assure very close balance at
baseline on age, sex, race/ethnicity, BMI and ACQ score
stratified by participating KPNC medical centers, and
better than chance balance on characteristics correlated
with the balancing variables. Within each medical center,
participants will be randomized in blocks to take advan-
tage of complete data on baseline covariates across the
recruited sample prior to randomization.
For the first block within a medical center, the imbal-
ance scores of all possible allocations with equal numbers
of participants between two anonymous groups (1 and 2)
will be calculated using equation 1. The correspondence
of groups 1 and 2 with either the WL or UC arm will be
assigned randomly at the outset and used consistently
throughout the trial.
where k is the kth balancing factor (k = 1 to 5) as listed
above;   and   are the average of kth factor for
groups 1 and 2, respectively; and the weights (w) deter-
mine the relative contribution of each balancing factor to
the imbalance B [30]. In BE WELL, equal weights will be
assumed for all balancing factors. For categorical factors,
orthogonal dummy variables, which identify individual
factor levels, will be coded before imbalance score calcu-
lation. A set of optimal allocations will be determined by
the lowest 1,000 calculated B values [30]. One allocation
will be randomly selected from the set of optimal alloca-
B =− () = ∑ wx x kk k k
m
12 1
2
(1)
x k 1 x k 2
Table 1: Participant inclusion and exclusion criteria
Inclusion criteria
* Age (as of date of enrollment)
- Lower age limit: 18 years
- Upper age limit: 70 years
* Gender: Both men and women
* Race/ethnicity: All racial and ethnic groups
* Body mass index 30.0-44.9 kg/m2
* Suboptimally controlled asthma:
- Documented diagnosis of asthma on the current 
medical problem list
- Currently prescribed an anti-asthma medication
- Score <20 on the Asthma Control Test [75]
- Demonstrable airway reversibility
* Kaiser member for ≥ 1 year
* Able and willing to enroll and provide written, informed 
consent, i.e., to: 1) meet the time and data collection 
requirements of the study; 2) be randomized to one of the 
two intervention arms; 3) adhere to the recommendations of 
the study intervention as assigned; 4) participate in follow-
up for 12 months; and 5) allow extraction of relevant 
information from their medical records.
Exclusion criteria
* Inability to speak, read or understand English;
* Intermittent asthma, defined as either seasonal asthma or 
(daytime asthma symptoms <2×/week and nocturnal 
symptoms <2×/month and no use of controller 
medications);
* Diagnosis of COPD (emphysema or chronic bronchitis) 
suggested by patient report of doctor diagnosis, spirometry, 
and smoking history;
* Use of weight-loss medications in the past 3 months;
* Initiation or change of antidepressant medication within 
the past 3 months;
* Regular use (>5 days/month) of the following medications: 
oral corticosteroids, insulin, oral hypoglycemics, anti-
psychotics, and mood stabilizers;
* Currently enrolled in a group or individual intervention 
program that overtly aimed at weight loss, nutrition and/or 
physical activity at Kaiser or elsewhere;
* Planning to undergo bariatric surgery during the study 
period;
* Inability to perform pulmonary function tests by 
spirometry in a consistent manner;
* Having a medical or physical condition that makes 
moderate intensity physical activity (like a brisk walk) 
difficult or unsafe;
* Significant medical co-morbidities, including uncontrolled 
metabolic disorders (e.g., thyroid, renal, liver), diabetes, 
heart disease, stroke, and ongoing substance abuse;
* Hospitalization for psychological or emotional problems 
within the past two years;Ma et al. BMC Pulmonary Medicine 2010, 10:16
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tions for the block of participants about to be random-
ized.
After randomization of the first block of participants
within a medical center, allocations for each subsequent
block will be conditional on the chosen allocations of par-
ticipants in earlier blocks. The imbalance score B for a
new block will be computed using equation 2.
where n1 is the number of participants in the existing
block(s) and n2 is the total number of participants with
the addition of the new block; x1ik and x2ik represent the
kth factor of ith participant allocated in group 1 or 2. The
process of sampling from the 1,000 lowest calculated B
values will be repeated for all subsequent blocks.
This randomization procedure not only minimizes
imbalance for the chosen baseline covariates between
treatment groups and correlated characteristics, but also
ensures concealment of treatment allocation, with
recruitment staff completely unable to influence alloca-
tion. A designated research staff member who is not
involved in follow-up data collection or data analysis will
carry out randomization using a computerized program.
Anonymous labels of treatment assignments will be used
in all study reports and other materials to ensure blinding
of the investigators and staff responsible for follow-up
data collection and data analysis. Staff responsible for
delivering the WL intervention will be masked to all out-
come data until the end of trial. Due to the nature of this
intervention, blinding of the participants is not feasible.
Baseline and Follow-up Measures and Data Collection
Table 2 shows the study measures and data collection
schedule. In addition to the screening and baseline data
collection activities described previously, follow-up visits
for questionnaires, clinical measurements, and adverse
event monitoring will be conducted at six and 12 months
after randomization.
Primary and Secondary Outcomes
The primary outcome measure is the Juniper Asthma
Control Questionnaire (ACQ). The ACQ provides a reli-
able and validated measure of the impairment dimension
of asthma control [28,31] and includes specific measures
of each component of impairment as defined in the cur-
rent asthma treatment guidelines [22], i.e., daytime and
nocturnal asthma symptoms, functional capacity, rescue
medication use (excluding use for prevention of exercise-
induced bronchospasm), and lung function (FEV1). ACQ
is the only composite measure, among the several recom-
mended by the guidelines, that includes lung function in
its overall rating and is in widespread use in trials of both
asthma pharmacotherapeutic and behavioral interven-
tions [22].
Secondary outcomes include lung function measure-
ments by spirometry (Table 2) and the 15-item Juniper
Mini Asthma Quality of Life Questionnaire (mini-AQLQ)
[32]. In addition, asthma-related health care utilization
(HCU) will be assessed through data extraction from
KPNC electronic databases for the period of 12 months
pre- and post-randomization. These databases contain
information on all outpatient and inpatient HCU at KP
facilities, non-KP facilities with which KP contracts for
emergency and hospital services, and on reimbursable
emergency hospital care at non-contract facilities.
Although we will analyze HCU data according to type of
encounter, the primary HCU outcome will be the overall
rate of outpatient encounters and emergency department
and inpatient admissions with asthma as primary diagno-
sis. Data will also be extracted on current medications
prescribed and all asthma, allergic rhinitis, and GERD
medications dispensed for the same time periods. In KP,
it is estimated that well over 95% of all prescriptions are
filled at a KP pharmacy, and patients are very unlikely to
have concurrent non-KP sources of asthma care or phar-
macy. Therefore, dispensing records provide reliable and
unbiased information on medication refill adherence and
regimen potency. The former will be assessed by calculat-
ing continuous medication acquisition indices (the total
days supply of a given type of medication dispensed in a
given period of time as a proportion of the total days sup-
ply prescribed), for asthma controller and reliever medi-
cations separately. The total strength of all controller
medications dispensed in a given time period will be
expressed in beclomethasone-80 canister equivalents,
and the total strength of all reliever medications dis-
B =− () − (
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* Diagnosis of cancer (other than non-melanoma skin 
cancer) that is/was active or treated with radiation or 
chemotherapy within the past 2 years;
* Diagnosis of a terminal illness and/or in hospice care;
* Currently pregnant, lactating, or planning to become 
pregnant during the study period;
* Already enrolled or planning to enroll in a research study 
that would limit full participation in the study or confound 
the interpretation of the study's findings;
* Family/household member of another study participant or 
of a study staff member;
* No longer a Kaiser patient or planning to transfer care 
outside of Kaiser during the study period;
* PCP determination that the study is inappropriate or 
unsafe for the patient;
* Investigator discretion for clinical safety or protocol 
adherence reasons.
Table 1: Participant inclusion and exclusion criteria Ma et al. BMC Pulmonary Medicine 2010, 10:16
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Table 2: List of measures and data collection schedule
Baseline Follow-up month
61 2
Questionnaires
Juniper Asthma Control 
Questionnaire (ACQ)
XXX
Juniper Mini Asthma-specific 
Quality of Life Questionnaire 
(mini-AQLQ)
XXX
Two-week asthma symptom 
diary
XXX
Baseline Dyspnea Index X
Transition Dyspnea Index X X
Three-day food record X X X
Eating Habits Confidence 
Survey
XXX
Social Support and Eating 
Habits Survey
XXX
Stanford Seven-day Physical 
Activity Recall
XXX
Exercise Confidence Survey X X X
Total number of steps in the 
past seven days (per 
pedometer reading)
XXX
Social Support and Exercise 
Survey
XXX
Rose questionnaire for angina 
and peripheral vascular 
disease
XXX
Center for Epidemiologic 
Studies Depression Scale (CES-
D)
XXX
Depression Anxiety Stress 
Scale
XXX
Obesity Related Problems 
Scale
XXX
12-item Short Form Health 
Survey (SF-12)
XXX
Berlin Questionnaire for Sleep 
Apnea
XXX
Gastroesophageal Reflux 
Disease Symptom Assessment 
Scale
XXX
Adverse events X X X
Care at non-Kaiser health care 
facilities
XXX
Demographics X
Clinical Measures
Height XMa et al. BMC Pulmonary Medicine 2010, 10:16
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pensed in a given time period will be expressed in
a l b u t e r o l  ca n i s t e r  e q u i v a l e n t s,  as  w e  h a v e  d o n e  i n  o u r
previous research [33]. For combination medications
(e.g., fluticasone-salmeterol), each active ingredient com-
ponent of the medication will be counted separately and
all will contribute to the adherence and potency calcula-
tions.
Additional secondary outcomes include measurements
of waist circumference, hip circumference, and resting
blood pressure according to standardized protocols as
recommended by the PhenX project https://
www.phenx.org). Dyspnea with activities of daily living
will be assessed using a baseline dyspnea index to rate
severity of dyspnea at a single state and a transition dysp-
nea index that denotes changes from that baseline [34].
The 12-item Short Form Health Survey (SF-12) [35], a
widely used measure of generic health-related QoL, will
be administered to evaluate changes in non-disease spe-
cific physical and mental health status. The Obesity-
Related Problem Scale is a reliable eight-item scale that
measures the impact of obesity on psychosocial function-
ing and is responsive to weight loss intervention [36].
Mental health status will be assessed using the 20-item
Center for Epidemiological Studies Depression scale
(CES-D) [37] and the Depression Anxiety Stress Scale
[38]. In addition to asthma-related HCU, utilization for
other obesity-related co-morbidities, non-asthma pulmo-
nary diagnoses, and all other HCU will be assessed.
Potential Mediators
The intervention to be studied involves changes in diet
and physical activity aimed at producing weight loss.
Undoubtedly, there will be variation in changes in weight
loss, physical activity level, and diet. Also, some evidence
suggests that physical activity and certain nutrients may
have independent effects on asthma outcomes [39-44].
Investigating the relative contribution of changes in BMI,
physical activity, and diet will provide evidence of
whether the underlying mechanism for improvement in
asthma control is related to weight loss per se or not.
Caloric and nutrient intake will be determined from food
records collected on two non-consecutive weekdays and
one weekend day within a seven-day period at each
assessment point. Multiple-day food records are consid-
ered a gold standard for collection of individual dietary
data [45]. Food composition will be analyzed using the
Nutrition Data System. Physical activity will be measured
using the Stanford 7-Day Physical Activity Recall, which
is a reliable measure that is sensitive to change in physical
activity [46-48].
Weight, waist circumference, 
hip circumference, waist to 
hip ratio (WHR)
XXX
Blood pressure X X X
Spirometry: Forced maneuver 
- FEV1, FEV6, FVC (absolute 
and % predicted values), 
FEV1/FVC, FEV1/FEV6; Slow 
maneuver - VT, ERV, IC, VCin, 
VCex
XXX
Data from KPNC Electronic Databases
Current medical problems X X
Medications currently 
prescribed
XXX
Medications dispensed2 XX
Health care utilization2 XX
Primary care provider 
characteristics
XX
Recruitment and intervention process measures (monitored continuously)
Safety of participants in the intervention arm (monitored continuously)
1Pre- and post-bronchodilator spirometry will be obtained at baseline visit 1 to determine reversibility of airway obstruction, which is an 
eligibility criterion. Only pre-bronchodilator spirometry will be performed at baseline visit 2 and at 6- and 12-month assessments and the 
measurements obtained will be used for analysis.
2Data will be extracted for a period of 12 months before and after randomization.
Abbreviations: ERV, expiratory reserve volume; FEV1, forced expiratory volume in one second; FEV6, forced expiratory volume in six seconds; 
FVC, forced vital capacity; IC, inspiratory capacity; KPNC, Kaiser Permanente in Northern California; VCin and VCex, inspiratory and expiratory 
vital capacity; VT, tidal volume.
Table 2: List of measures and data collection schedule (Continued)Ma et al. BMC Pulmonary Medicine 2010, 10:16
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Potential Moderators
To elucidate differences in intervention effects among
subgroups of the study sample, we will collect data on
important socio-demographic characteristics: age, sex,
race/ethnicity, education, marital status, household
income, medical insurance, smoking status, and age at
onset of asthma symptoms. In addition, the Berlin Ques-
tionnaire for sleep apnea[49] and the Gastroesophageal
Reflux Disease (GERD) Symptom Assessment Scale[50]
will be used to screen for possible sleep disorders and
GERD, respectively, as these are common comorbidities
in obese individuals with or without asthma. Their pres-
ence may modify the intervention effect.
Process Measures
Data to assess the likelihood of potential subsequent
adoption of the weight loss intervention by the health
care system, such as the representativeness of physician
approval of their patients' participation, patient willing-
ness to enroll in the study, and reasons for declining to
participate will be documented. Intervention process
measures will include dates and number of classes
attended, number and duration of in-clinic visits and
phone calls, patient self-monitoring records, and data
electronically stored in pedometers provided to partici-
pants by the study.
Interventions
Theoretical Basis
The theoretical underpinning of the BE WELL weight
loss intervention is derived from Social Cognitive Theory
[51] and the Transtheoretical Model of Behavior Change
[52]. The former emphasizes the reciprocal determinism
between individual, environment, and behavior, whereas
the latter recognizes that behavior change is a dynamic
process that moves, at variable speed, through stages of
readiness to change. Behavior change is more likely with
increased behavior capability, and behavior capability is
strengthened through goal setting, skill building and self-
monitoring [51]. Also important are confidence in one's
ability to perform a given behavior (self-efficacy) and
expectation of favorable outcomes of the behavior (out-
c o m e  e x p e c t a t i o n s ) .  B e h a v i o r a l  s t r a t e g i e s  m a y  v a r y  b y
stage of change (i.e., experiential processes during initial
phases of behavioral adoption and behavioral processes
occurring during action and maintenance phases) [52]. In
addition, the BE WELL intervention draws upon key
research evidence for the importance of self-management
in chronic disease management [53-55]. Successful self-
management intervention is driven by patient-defined
problems and fosters the mastery of skills in problem
solving, action planning, decision making, and support
building through an iterative process [55,56].
Furthermore, the BE WELL intervention is based on
the premise that long-term changes in diet and exercise
and sustained motivation to maintain behavior changes
are most likely to occur when the strategies used to moti-
vate and support behavior change are flexible, sensitive to
cultural and individual differences, and broadly accept-
able to those in the target population. We make use of a
combination of a structured protocol (in which all partic-
ipants receive certain common core information) and
individually tailored strategies to help each participant
achieve and maintain specific physical activity and
dietary changes directed toward the overall intervention
goals of losing weight and increasing physical activity.
The BE WELL intervention clearly differs from the
delivery of lifestyle modifications in the usual primary
care setting. Current practice routinely involves physician
advice, occasionally with referral to a dietitian who takes
a diet history and who then provides standard educa-
tional materials and advice during a small number of
individual or group sessions, typically with little or no fol-
low-up. This standard clinical approach lacks the theoret-
ical basis and behavioral self-management focus
described above.
Evidence-based Intervention Goals
A goal-based approach is used in the BE WELL interven-
tion in which participants will be given the same weight
loss and physical activity goals. The weight goal is to
achieve and maintain a weight loss of 7% of baseline body
weight in a gradual stepwise fashion. A 7% weight loss has
proven to be feasible and safe and is associated with clini-
cally significant reductions in the risk of diabetes and car-
diovascular disease [57-60]. Participants who wish to lose
more than 7% of their starting weight may be encouraged
to do so only insofar as the participant maintains a nor-
mal BMI at or above 21 and the rate of weight loss does
not exceed three pounds per week. The physical activity
goal is to achieve and maintain a minimum of 150 min-
utes per week of moderate intensity physical activity
(such as brisk walking). This goal is consistent with the
new Physical Activity Guidelines for Americans [61], and
is deemed safe and attainable for most adults, including
those with chronic conditions such as asthma. Partici-
pants, especially those who are habitually sedentary, will
be advised to gradually and steadily increase daily walk-
ing with a goal of achieving 150 minutes of brisk walking
per week by the end of the Intensive intervention stage in
month 4. Regular physical activity recommendations for
activities of moderate intensity other than brisk walking,
as well as strength and flexibility physical activities, will
be tailored to the participant's situation [62,63]. After
attaining the minimum goal of 150 minutes per week,
participants who wish to be more active will be encour-
aged to do so, as tolerated. If participants reach the 150-
minute goal but are not achieving the weight goal, they
will be encouraged to further gradually increase their
physical activity to 60 minutes/day of moderate physicalMa et al. BMC Pulmonary Medicine 2010, 10:16
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activity [62,64,65] as well as to consider further calorie
restriction.
To help them achieve and maintain the weight goal,
participants also will be given a goal for daily calories. A
moderate reduction of caloric intake by 500-1000 kcal/
day has been shown to produce clinically significant
weight loss over time and is a safe and achievable goal for
most people [27]. Of note, the calorie goals will be given
as a means to achieve and maintain the weight goal,
rather than as a goal in and of itself. Therefore, if a partic-
ipant consumes more than the assigned calorie goal, but
is achieving the weight goal, there is no need to focus on
further reductions. Participants will be encouraged to
gradually achieve the calorie goals through portion con-
trol, choices of low-energy and nutrient-dense meals and
snacks, healthy food preparation techniques, and careful
selection of restaurants, including fast food, and of the
items offered. Participants also will be advised to: (1)
lower saturated fat intake to <10% of caloric intake, (2)
lower cholesterol intake to <300 mg/day, (3) consume a
high plant-based diet that includes a variety of vegetables,
beans, whole grains, low-fat dairy products, and whole
fruits, and (4) reduce intake of high glycemic index carbo-
hydrates.
Intervention Format, Structure, and Content
Participants in both the UC and WL arms will continue
to receive the standard of medical care from their PCPs
and any specialists, per KPNC treatment protocols. In
addition, they will receive an Omron HJ-7201ITC
pedometer, which records steps taken, and an HBF-400
scale for home weight measurement. They will also
receive KPNC standard asthma self-management and
weight management educational handouts and a list of
elective weight management services offered at the par-
ticipating medical centers.
In addition to usual care, participants in the WL arm
will progress through three successive intervention
stages: Intensive, Transitional and Extended stages. Table
3 shows the design elements of the BE WELL interven-
tion during the three stages.
Intensive Stage The Intensive stage of the BE WELL
intervention is adapted from the Group Lifestyle Balance
(GLB) program™ [66]. The GLB program is based on the
highly successful Diabetes Prevention Program [57] and
includes 12 weekly small group sessions. Each session fol-
lows a similar structure and includes five curriculum
components: 1) measurement and recording of weight, 2)
review of self-monitoring records and progress, 3) identi-
fication of personal barriers to weight loss and activity
and potential solutions, 4) presentation of a new content
area, and 5) goal setting and action plans for next week.
In BE WELL, the GLB Manual of Operations will be
closely followed, except for the addition of a food tasting
activity as part of the check-in process and a 30-minute
segment of physical activity demonstrations and practices
at the end of each session. The food tasting activities are
aimed at increasing participant experience with healthy
food choices, encouraging them to try new foods that
they might not normally try on their own, and stimulat-
ing a social, fun and engaging environment. The physical
activity demonstrations and practices are aimed at
increasing participant awareness of physical activity
intensity, experiencing various moderate-intensity activi-
ties that are safe and that they can easily incorporate into
their daily lives, and increasing participant confidence. As
part of these supervised exercises, participants will learn
how to recognize exercise-induced bronchospasm based
on symptoms and peak flow meter readings and the
appropriate prophylaxis and treatment. In BE WELL,
participants will be given a pedometer and start using it
to record their daily steps in week 1, as opposed to start-
ing this in week 10 as in the original GLB program. Fur-
thermore, BE WELL participants will attend an
additional group session focusing on the latest evidence
that came out after the GLB program on high-carbohy-
drate and high-fat/high-protein dietary approaches to
weight loss to complement the program's emphasis on
low-fat diets. The 13 group sessions of 90-120 minutes
each will be delivered by a nutrition health educator and a
fitness instructor over a 4-month period.
Transitional Stage In the Transitional stage, participants
will attend one individual counseling session in month 5
and another one in month 6. The goals of these visits are
to 1) finalize a customized, comprehensive action plan for
weight loss and maintenance viable in the participant's
environment, and 2) facilitate participant independence
in carrying out and maintaining that behavior change as
the influence of the interventionists diminishes. During
the sessions, interventionists will review and discuss the
participant's self-monitoring records of weight, dietary
intake and physical activity, provide feedback on progress
(or lack thereof), discuss barriers to behavior change, and
will advise on problem solving and relapse prevention
strategies.
Extended Stage The goal of the remaining 6 month will
be to facilitate the continued evolution of behavior
changes achieved to date and to promote long-term
weight stability. Participants will continue to monitor
their weight, dietary intake, and physical activity based
on their care plan. Interventionists will monitor the prog-
ress of each individual and provide individualized feed-
b a c k  a n d  s t r u c t u r e d  g u i d a n c e  b y  p h o n e  a t  l e a s t  b i -
monthly. Participants may initiate contact with the inter-
ventionists at any point. At the discretion of the interven-
tionists, participants may be seen in person to address
outstanding issues related to poor understanding of and/
or adherence to the intervention protocol. Participants
with weight gains of 3 to 5 lbs (1.4 to 2.2 kg) will be tele-Ma et al. BMC Pulmonary Medicine 2010, 10:16
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phoned on a biweekly basis until they return to a stable,
lower weight. A weight gain of 5 lbs (2.3 kg) or more will
automatically trigger a suggestion of an in-clinic visit at
which the participant will be encouraged to restart or
intensify active weight-loss efforts and a new action plan
will be created to guide the efforts.
Participant Safety
Participants will be carefully screened, and individuals for
whom the intervention is deemed medically inappropri-
ate or unsafe will be excluded. PCP approval will be
required before potentially eligible patients are contacted
by the study. During screening, women who are pregnant,
lactating, or planning to become pregnant during the
study period will be excluded. If a participant becomes
pregnant during the study, she will be excluded from fur-
ther participation in all study activities, and her PCP will
be notified. Participants who are diagnosed with any
other exclusionary condition (e.g., coronary heart dis-
ease, stroke, diabetes, cancer) following randomization
may continue with the intervention (if applicable) and fol-
low-up assessments only after explicit approval of a study
physician.
Surveillance for adverse events and relevant clinical
events will occur by questionnaire at regularly scheduled
assessment points and by systematic query of all partici-
pants' electronic health records at three month intervals
throughout the follow-up. Similar information reported
by participants at other times (e.g., during intervention
encounters) will be duly noted and followed up to assure
participant safety. A study physician will review all
adverse event reports to determine whether they are seri-
ous, study related, or expected, and the events will be
reported to the IRB, DSMB, and the sponsor according to
the reporting timelines appropriate to the type of the
event.
Alert levels (e.g., for lung function and blood pressure)
and alert conditions (e.g., asthma exacerbations, cardio-
vascular events, musculoskeletal injuries) and referral
protocols have been established to ensure that partici-
pants are offered appropriate evaluation and therapy
when clinically indicated. In all cases, participants may be
immediately referred for medical evaluation as needed or
recommended by the study clinician.
Retention
Adherence and retention in BE WELL is expected to be
fostered by: 1) selection/retention of qualified staff, their
training, and systematic quality control; 2) the relation-
ship between staff and participants, 3) willingness to
accommodate participant schedules and needs, and 4)
resourcefulness and persistence of the staff. For purposes
of follow-up assessment, a participant tracking database
will be used to assure that participants are contacted on a
timely basis. Subjects' contact information will be kept
current and at least two alternative contacts will be col-
lected. Subjects will be given a nominal payment for each
data collection visit. Assessment staff, who will be
blinded to treatment assignment, will contact subjects
who miss a visit to reschedule the visit and to re-engage
them in subsequent follow-ups. Subjects will be educated
about the importance of follow-up assessment even if
Table 3: Design elements of the BE WELL weight loss intervention
Stage Intensive (Months 1-4) Transitional (Months 5-6) Extended (Months 7-12)
Goal of contact Gradual weight loss associated with small, progressive changes in 
diet and physical activity
Weight maintenance or 
continued gradual weight loss
Contact schedule Weekly (13 contacts) Monthly (2 contacts) Bi-monthly/monthly (typically 
3-6 contacts)
Contact mode Group, in person (Family 
member welcome)
Individual, in person (Family 
member welcome)
Individual, by phone (in 
person as needed)
Contact duration 90-120 minutes 30-60 minutes Variable
Contact structure * Private weigh-in
* Review and sharing of 
progress, or lack thereof, in 
relation to action plan/goals 
from last session
* Didactic presentation of a 
new topic
* 30-minute supervised 
physical activity session
* Development of individual 
action plan/goals for the next 
week
* Private weigh-in
* Review of self-monitoring 
records
* Identification of personal 
barriers to weight loss and 
activity
* Problem solving and relapse 
prevention
* Development/revision of a 
customized care plan
* Review of self-monitoring 
records
* Detection of signs of non-
adherence and relapse
* Problem solving to 
encourage adherence and 
prevent relapse
* Revision of the customized 
care plan
* If indicated, re-initiation of 
intensive weight loss efforts 
through individual or small 
group visitsMa et al. BMC Pulmonary Medicine 2010, 10:16
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they are not adhering to the treatment. Priorities will be
given to the primary and main secondary outcomes in
cases where not all follow-up measurements may be
obtained from a subject.
Ongoing monitoring of indices of participation in inter-
vention activities helps interventionists identify partici-
pants who are having problems adhering to the
intervention protocol and thus initiate recovery efforts.
Such efforts can range from brief telephone discussion to
an individual counseling session with the interventionist
in which the participant who makes a decision to discon-
tinue intervention can review concerns regarding BE
WELL, reasons for staying in the study, and decisions
about remaining a participant. Unless the participant
declines, the interventionist will continue to contact the
participant on a progressively less frequent schedule,
starting monthly and decreasing to semi-annually to
remind her/him of the opportunity to re-enter BE WELL.
Sample size consideration and statistical analysis
Sample Size
In the only RCT conducted to date of lifestyle-induced
(by caloric restriction and behavior change) weight loss
for the management of asthma, effect size (Cohen's d)
estimates ranged between 0.4 and 0.6 for various asthma
symptom and lung function outcomes over a 12-month
follow-up period [26]. A sample size of 324 is sufficient to
detect an effect size of 0.4 between the WL and UC arms
for 90% power at 5% alpha 2-sided, assuming up to a 20%
loss to 12-month follow-up (or an end-of-the-study sam-
ple size of 259). The power estimate was calculated based
on an independent t-test using simplified assumptions.
Note that the t-test calculation is conservative because it
does not account for variance reduction due to adjust-
ment for repeated measures, nor for the better than
chance comparability of the experimental groups.
Statistical analysis
The primary hypothesis compares Juniper ACQ scores
between the WL and UC arms at 12 months using an
intent-to-treat analysis. Linear mixed modeling, using
SAS PROC MIXED [67] will test time and group interac-
tions to assess whether within-subject change in Juniper
ACQ scores differs by condition (equation 3).
Due to randomization, the distributions of baseline val-
ues on the dependent variable (Y0) and baseline covari-
ates (Xi where i = 1 to k) should be similar between
treatment arms and thus not bias the analysis. Nonethe-
less, to the extent they are associated with the outcome,
their inclusion in the model will account for otherwise
unexplained variation and hence increase the efficiency
of the analysis. In addition, their inclusion will guard
against imbalance in the distributions of these covariates
between treatment arms, which can still occur despite
randomization. a, g, and δ represent the random effects
caused by clustering of patients with physicians and, in
turn, physicians within clinics, and by blocking of
patients within medical centers. ε takes into account the
correlation of repeated measures within subjects.
The same analysis strategy is appropriate for evaluating
secondary aims where the hypotheses are identical but
with different outcome measures (e.g., lung function,
asthma-specific QoL, asthma-related HCU). The longitu-
dinal effects of the intervention will be assessed using the
same model, except that the focus is comparisons within
the intervention arm at different time points. Analyses
will also be conducted to examine whether there is a
dose-response relationship between intervention adher-
ence and outcome, where dose is defined in terms of
number of group sessions attended, number of self-moni-
toring logs kept, average daily intakes of calories and fat,
and average number of minutes of physical activity per
week.
The primary analyses will be intention-to-treat. Sec-
ondary per-protocol or as-treated analyses will be per-
formed to help elucidate the primary findings. For
subjects with missing data at follow-up, we will conduct
and report on sensitivity analyses in which several previ-
ously recommended approaches for handling missing
data in longitudinal trials will be used, e.g., multiple
imputation and the pattern-mixture model [68].
We will use the MacArthur approach, which modified
the Baron & Kenny criteria, for defining moderators and
mediators in clinical research studies [69]. Let T be the
treatment, M be the potential moderator or mediator,
and O be the outcome. Association between T, M, and O
is examined using the following models:
M can be considered a mediator of the effect of T on O
if T precedes M, γ1 ≠ 0, and either β2 ≠ 0 or β3 ≠ 0. M is a
moderator of the effect of T on O if M precedes T, γ1 = 0,
and β3 ≠ 0.
Data Management
All study data will be entered into computerized data files
utilizing: 1) Microsoft Access for participant tracking and
i n t e r v e n t i o n  d a t a  e n t r y ,  2 )  V o v i c i ' s  s u r v e y  s o f t w a r e
(Dulles, VA) for self-administered questionnaires and
entry of clinical measurements, 3) the Nutrition Data
System for nutrient analysis based on three-day food
YT R T Y T T R T T X 112 3 4 4 i i =+ + + + () ++ + + mb b b b b ag 0 * Σ
M1 T =+ + gg e 0 (4)
O1 T 2 M 3 T M =+ + + + bb b b e 0 (5)Ma et al. BMC Pulmonary Medicine 2010, 10:16
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records, and 4) a custom-designed web application for
s e v e n - d a y  p h y s i c a l  a c t i v i t y  r e c a l l  d a t a  e n t r y .  R e s e a r c h
assistants (blinded to participant group assignments) will
review participant responses on questionnaires with par-
ticipants present, and skipped or incorrectly addressed
items will be brought to the participant to correct. All of
the data entry systems employ automatic, real-time
range, logic, and missing value checks. Data sets will be
cleaned, verified and archived, and then read into SAS
(Enterprise Guide 4.1; SAS Institute, Cary, NC) data sets,
which also will be archived. One official copy of all the
s t udy da ta  a nd a  m ast e r da ta  dict iona ry wil l be  m a in-
tained and updated regularly by the study data analyst.
All analytic and tracking database files will be stored in a
secure network drive with daily backups. One copy of the
backups will be saved on-site and one off-site. Separate
archival databases will be permanently maintained. The
data files can be shared by authorized study personnel
both on-site and in remote locations via a secure virtual
private network. Data security will be ensured through
password protection and data encryption.
Protected health information will be used and disclosed
in accordance with the HIPAA regulations.
Treatment Fidelity
Intervention quality assurance procedures ensure that
project activities are standardized across the interven-
tionists and across the cohorts and that intervention pro-
cess data are collected accurately. To achieve this,
standardized protocols, procedures, and educational
materials are prepared, and staff are systematically
trained in their use. Provider and auditor checklists are
created to ensure that the intervention protocols are fol-
lowed and that treatment objectives for each group ses-
sion are met. Interventionists will complete a Provider
Checklist after each session. All group and individual ses-
sions will be audiotaped and a random sample of 10%
selected for rating by a qualified individual using the
Auditor Checklist. When a session is reviewed with less
than 85% of treatment-specific objectives met, the audi-
tor will inform the PI who will remediate interventionist
training as needed. This process will continue through all
treatment waves so that interventionist drift can be
swiftly and consistently corrected.
Discussion
On a population basis, the high prevalence of obesity
among adults with asthma suggests an important oppor-
tunity to improve the lives of many such individuals.
While the clinical treatment of asthma should continue to
emphasize implementation of proven pharmacological
and patient self-management strategies [22], the available
evidence is already sufficient to warrant the investigation
of including evidence-based weight loss strategies as an
adjunct therapy for asthma patients who are also obese.
Intensive weight loss interventions that employ a combi-
nation of recommended dietary, physical activity, and
behavioral strategies have consistently resulted in weight
losses in the range of 5-7%, which are associated with sig-
nificantly reduced risk of well-recognized co-morbidities
of obesity, such as diabetes and hypertension [57-60]. The
efficacy of such a comprehensive, evidence-based, life-
style approach to weight loss in improving asthma out-
comes has not been investigated for obese individuals
with asthma.
In BE WELL, the primary objective is to investigate
whether weight loss, resulting from dietary modification,
physical activity and behavior change, has significant
clinical benefits for improving asthma control in obese
adults. To our knowledge, BE WELL is the first study with
adequate design and power for investigating the longitu-
dinal effects of a behavioral weight loss intervention on
asthma control. The only RCT for a similar purpose pub-
lished to date was conducted by Stenius-Aarniala et al.
[26] with the sample of 38 adult obese asthmatics. The
results showed a net mean weight loss of 9.1%, which was
associated with significant improvements in self-reported
asthma symptoms and objectively assessed lung function
(by spirometry) over 12 months. Other, non-randomized
studies reported that weight loss induced by surgery [70-
72] or dietary restriction [23,24,26,73] was associated
with improved asthma symptoms, lung function, medica-
tion use, quality of life, and health care utilization.
The targeted clinical population in BE WELL is impor-
tant from the standpoint of its risk for poor asthma out-
comes, as well as metabolic and cardiovascular disease.
For such individuals, weight loss through intensive life-
style intervention, rather than surgical intervention or
dietary restriction alone, is recommended as first-line
therapy. Weight loss is recommended for obese patients
with asthma by The National Asthma Education and Pre-
vention Program Expert Panel Report 3 [22], but a lack of
strong evidence of the efficacy of weight loss for improv-
ing asthma control was recognized by the Expert Panel.
BE WELL will provide objective evidence on whether a
state-of-the-art weight loss lifestyle intervention achieves
a statistically and clinically meaningful improvement over
a year's follow-up in asthma control and other manifesta-
tions that EPR3 considers indicative of current impair-
ment (symptoms, lung function, rescue medication use,
asthma-specific quality of life) and future risk (asthma
exacerbations and medication side effects).
Achieving the goals of this study holds considerable
potential for advancing the understanding of the causality
of the obesity-asthma association and identifying effec-
tive behavioral approaches for the management of
asthma in adults with comorbid obesity. This study will
also serve as a foundation for future studies aimed atMa et al. BMC Pulmonary Medicine 2010, 10:16
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Page 12 of 14
understanding the mechanisms by which weight loss is
expected to improve asthma control, which may also illu-
minate the mechanism(s) linking obesity and the devel-
o p m e n t  o f  a s t h m a .  F u t u r e  r e s e a r c h  i s  a l s o  n e e d e d  t o
investigate the effect of weight loss on asthma control
among children - a significantly under-researched area
even compared to the limited research in adults [74].
Findings from this RCT, if as projected, will strengthen
current guidelines for treating obese adults with asthma,
which may lead to reduced morbidity and mortality
related to both chronic diseases.
Competing interests
Dr. Camargo has received financial support from a variety of groups for partici-
pation in conferences, consulting, and medical research. During 2005 to 2010,
industry sponsors with an interest in asthma were AstraZeneca, Critical Thera-
peutics, Dey, Genentech, GSK, Merck, Novartis, Respironics, and Schering-
Plough. Dr. Buist is a member of advisory boards for AstraZeneca, Merck, GSK,
Sepracor, Pfizer and Novartis.
All other authors declare that they have no financial, research, organizational,
or other interests to disclose that are relevant to the execution of this research
or this publication.
Authors' contributions
JM conceived of the study, has the overall responsibility for its design and con-
duct, and drafted the manuscript. LX and EA contributed to drafting the manu-
script and LX also contributed to the design of the statistical analysis. PS, CAC,
CDG, ASB, WLH, PWL, SRW participated in the design of the study and revised
the manuscript critically for important intellectual content. All authors read
and approved the final manuscript.
Acknowledgements
The project described is supported by Award Number R01HL094466 from the 
National Heart, Lung and Blood Institute. The content is solely the responsibil-
ity of the authors and does not necessarily represent the official views of the 
National Heart, Lung and Blood Institute or the National Institutes of Health. 
The authors would like to acknowledge the Diabetes Prevention Support Cen-
ter of the University of Pittsburgh Diabetes Institute for the development of 
and the training and support for implementation and maintenance of the 
Group Lifestyle Balance program.
Author Details
1Department of Health Services Research, Palo Alto Medical Foundation 
Research Institute, Palo Alto, CA, USA, 2Department of Allergy, Asthma, and 
Immunology, The Permanente Medical Group, San Francisco Medical Center, 
San Francisco, CA, USA, 3Department of Emergency Medicine, Massachusetts 
General Hospital, Harvard Medical School, Boston, MA, USA, 4Department of 
Pulmonary Medicine & Critical Care, Stanford University School of Medicine, 
Stanford, CA, USA, 5Stanford Prevention Research Center, Stanford University 
School of Medicine, Stanford, CA, USA, 6Pulmonary & Critical Care Medicine, 
Oregon Health & Science University, Portland, OR, USA and 7Department of 
Health Research & Policy, Stanford University School of Medicine, Stanford, CA, 
USA
References
1. Masoli M, Fabian D, Holt S, Beasley R: The global burden of asthma: 
executive summary of the GINA Dissemination Committee report.  
Allergy 2004, 59:469-478.
2. World Health Organization: Obesity: preventing and managing the 
global epidemic.  In WHO Technical Report Series 894 Geneva, Switzerland: 
WHO; 2000. 
3. Beuther DA, Sutherland ER: Overweight, obesity, and incident asthma: a 
meta-analysis of prospective epidemiologic studies.  Am J Respir Crit 
Care Med 2007, 175:661-666.
4. Ford ES: The epidemiology of obesity and asthma.  J Allergy Clin Immunol 
2005, 115:897-909. quiz 910
5. Shore SA, Johnston RA: Obesity and asthma.  Pharmacol Ther 2006, 
110:83-102.
6. Carroll CL, Bhandari A, Zucker AR, Schramm CM: Childhood obesity 
increases duration of therapy during severe asthma exacerbations.  
Pediatr Crit Care Med 2006, 7:527-531.
7. Lavoie KL, Bacon SL, Labrecque M, Cartier A, Ditto B: Higher BMI is 
associated with worse asthma control and quality of life but not 
asthma severity.  Respir Med 2006, 100:648-657.
8. Saint-Pierre P, Bourdin A, Chanez P, Daures JP, Godard P: Are overweight 
asthmatics more difficult to control?  Allergy 2006, 61:79-84.
9. Akerman MJ, Calacanis CM, Madsen MK: Relationship between asthma 
severity and obesity.  J Asthma 2004, 41:521-526.
10. Dixon AE, Shade DM, Cohen RI, Skloot GS, Holbrook JT, Smith LJ, Lima JJ, 
Allayee H, Irvin CG, Wise RA: Effect of obesity on clinical presentation 
and response to treatment in asthma.  J Asthma 2006, 43:553-558.
11. Peters-Golden M, Swern A, Bird SS, Hustad CM, Grant E, Edelman JM: 
Influence of body mass index on the response to asthma controller 
agents.  Eur Respir J 2006, 27:495-503.
12. Chinn S, Downs SH, Anto JM, Gerbase MW, Leynaert B, de Marco R, Janson 
C, Jarvis D, Kunzli N, Sunyer J, et al.: Incidence of asthma and net change 
in symptoms in relation to changes in obesity.  Eur Respir J 2006, 
28:763-771.
13. Chen Y, Dales R, Tang M, Krewski D: Obesity may increase the incidence 
of asthma in women but not in men: longitudinal observations from 
the Canadian National Population Health Surveys.  Am J Epidemiol 2002, 
155:191-197.
14. Hancox RJ, Milne BJ, Poulton R, Taylor DR, Greene JM, McLachlan CR, 
Cowan JO, Flannery EM, Herbison GP, Sears MR: Sex differences in the 
relation between body mass index and asthma and atopy in a birth 
cohort.  Am J Respir Crit Care Med 2005, 171:440-445.
15. Kim S, Camargo CA Jr: Sex-race differences in the relationship between 
obesity and asthma: the behavioral risk factor surveillance system, 
2000.  Ann Epidemiol 2003, 13:666-673.
16. Johnston RA, Theman TA, Shore SA: Augmented responses to ozone in 
obese carboxypeptidase E-deficient mice.  Am J Physiol Regul Integr 
Comp Physiol 2006, 290:R126-133.
17. Lu FL, Johnston RA, Flynt L, Theman TA, Terry RD, Schwartzman IN, Lee A, 
Shore SA: Increased pulmonary responses to acute ozone exposure in 
obese db/db mice.  Am J Physiol Lung Cell Mol Physiol 2006, 290:L856-865.
18. Shore SA, Rivera-Sanchez YM, Schwartzman IN, Johnston RA: Responses 
to ozone are increased in obese mice.  J Appl Physiol 2003, 95:938-945.
19. Tantisira KG, Weiss ST: Complex interactions in complex traits: obesity 
and asthma.  Thorax 2001, 56(Suppl 2):ii64-73.
20. Weiss ST, Shore S: Obesity and asthma: directions for research.  Am J 
Respir Crit Care Med 2004, 169:963-968.
21. Schaub B, von Mutius E: Obesity and asthma, what are the links?  Curr 
Opin Allergy Clin Immunol 2005, 5:185-193.
22. National Asthma Education and Prevention Program: Expert Panel 
Report 3 (EPR 3): Guidelines for the Diagnosis and Management of 
Asthma.  Bethesda, MD: National Institutes of Health; 2007. 
23. Aaron SD, Fergusson D, Dent R, Chen Y, Vandemheen KL, Dales RE: Effect 
of weight reduction on respiratory function and airway reactivity in 
obese women.  Chest 2004, 125:2046-2052.
24. Hakala K, Stenius-Aarniala B, Sovijarvi A: Effects of weight loss on peak 
flow variability, airways obstruction, and lung volumes in obese 
patients with asthma.  Chest 2000, 118:1315-1321.
25. Johnson JB, Summer W, Cutler RG, Martin B, Hyun DH, Dixit VD, Pearson 
M, Nassar M, Tellejohan R, Maudsley S, et al.: Alternate day calorie 
restriction improves clinical findings and reduces markers of oxidative 
stress and inflammation in overweight adults with moderate asthma.  
Free Radic Biol Med 2007, 42:665-674.
26. Stenius-Aarniala B, Poussa T, Kvarnstrom J, Gronlund EL, Ylikahri M, 
Mustajoki P: Immediate and long term effects of weight reduction in 
obese people with asthma: randomised controlled study.  Bmj 2000, 
320:827-832.
27. NHLBI: Practical Guide to the Identification, Evaluation and Treatment 
of Overweight and Obesity in Adults.  Bethesda, MD: Public Health 
Service, U.S. Department of Health and Human Services; 2000. 
Received: 3 March 2010 Accepted: 24 March 2010 
Published: 24 March 2010
This article is available from: http://www.biomedcentral.com/1471-2466/10/16 © 2010 Ma et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. BMC Pulmonary Medicine 2010, 10:16Ma et al. BMC Pulmonary Medicine 2010, 10:16
http://www.biomedcentral.com/1471-2466/10/16
Page 13 of 14
28. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR: Development and 
validation of a questionnaire to measure asthma control.  Eur Respir J 
1999, 14:902-907.
29. Carter BR, Hood K: Balance algorithm for cluster randomized trials.  BMC 
Med Res Methodol 2008, 8:65.
30. Raab GM, Butcher I: Balance in cluster randomized trials.  Stat Med 2001, 
20:351-365.
31. Juniper EF, Bousquet J, Abetz L, Bateman ED: Identifying 'well-controlled' 
and 'not well-controlled' asthma using the Asthma Control 
Questionnaire.  Respir Med 2006, 100:616-621.
32. Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR: Development and 
validation of the Mini Asthma Quality of Life Questionnaire.  Eur Respir J 
1999, 14:32-38.
33. Wilson SR, Strub P, Buist AS, Knowles SB, Lavori PW, Lapidus J, Vollmer WM: 
Shared treatment decision making improves adherence and outcomes 
in poorly controlled asthma.  Am J Respir Crit Care Med 181:566-577.
34. Mahler DA, Weinberg DH, Wells CK, Feinstein AR: The measurement of 
dyspnea. Contents, interobserver agreement, and physiologic 
correlates of two new clinical indexes.  Chest 1984, 85:751-758.
35. Ware J Jr, Kosinski M, Keller SD: A 12-Item Short-Form Health Survey: 
construction of scales and preliminary tests of reliability and validity.  
Med Care 1996, 34:220-233.
36. Karlsson J, Taft C, Sjostrom L, Torgerson JS, Sullivan M: Psychosocial 
functioning in the obese before and after weight reduction: construct 
validity and responsiveness of the Obesity-related Problems scale.  Int J 
Obes Relat Metab Disord 2003, 27:617-630.
37. Radloff L: The CES-D scale: A self-report depression scale for research in 
the general population.  Appl Psychological Measurement 1977, 
1:385-401.
38. Antony MM, Bieling PJ, Cox BJ, Enns MW, Swinson RP: Psychometric 
properties of the 42-item and 21-item versions of the Depression 
Anxiety Stress Scales (DASS) in clinical groups and a community 
sample.  Psychological Assessment 1998, 10:176-181.
39. Cochrane LM, Clark CJ: Benefits and problems of a physical training 
programme for asthmatic patients.  Thorax 1990, 45:345-351.
40. Mohsenin V, Dubois AB, Douglas JS: Effect of ascorbic acid on response 
to methacholine challenge in asthmatic subjects.  Am Rev Respir Dis 
1983, 127:143-147.
41. Robinson DM, Egglestone DM, Hill PM, Rea HH, Richards GN, Robinson 
SM: Effects of a physical conditioning programme on asthmatic 
patients.  N Z Med J 1992, 105:253-256.
42. Schachter EN, Schlesinger A: The attenuation of exercise-induced 
bronchospasm by ascorbic acid.  Ann Allergy 1982, 49:146-151.
43. Spector SL, Surette ME: Diet and asthma: has the role of dietary lipids 
been overlooked in the management of asthma?  Ann Allergy Asthma 
Immunol 2003, 90:371-377. quiz 377-378, 421
44. Broughton KS, Johnson CS, Pace BK, Liebman M, Kleppinger KM: Reduced 
asthma symptoms with n-3 fatty acid ingestion are related to 5-series 
leukotriene production.  Am J Clin Nutr 1997, 65:1011-1017.
45. Block G: A review of validations of dietary assessment methods.  Am J 
Epidemiol 1982, 115:492-505.
46. Blair SN, Haskell WL, Ho P, Paffenbarger RS Jr, Vranizan KM, Farquhar JW, 
Wood PD: Assessment of habitual physical activity by a seven-day 
recall in a community survey and controlled experiments.  Am J 
Epidemiol 1985, 122:794-804.
47. Dunn AL, Marcus BH, Kampert JB, Garcia ME, Kohl HW, Blair SN: Reduction 
in cardiovascular disease risk factors: 6-month results from Project 
Active.  Prev Med 1997, 26:883-892.
48. Young DR, Haskell WL, Taylor CB, Fortmann SP: Effect of community 
health education on physical activity knowledge, attitudes, and 
behavior. The Stanford Five-City Project.  Am J Epidemiol 1996, 
144:264-274.
49. Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP: Using the Berlin 
Questionnaire to identify patients at risk for the sleep apnea 
syndrome.  Ann Intern Med 1999, 131:485-491.
50. Rothman M, Farup C, Stewart W, Helbers L, Zeldis J: Symptoms associated 
with gastroesophageal reflux disease: development of a questionnaire 
for use in clinical trials.  Dig Dis Sci 2001, 46:1540-1549.
51. Bandura A: Social Foundations of Thought and Action: A Social Cognitive 
Theory Englewood Cliffs, N.J.: Prentice Hall; 1986. 
52. Prochaska JO, DiClemente CC: Stages and processes of self-change of 
smoking: toward an integrative model of change.  J Consult Clin Psychol 
1983, 51:390-395.
53. Bodenheimer T, Lorig K, Holman H, Grumbach K: Patient self-
management of chronic disease in primary care.  Jama 2002, 
288:2469-2475.
54. Holman H, Lorig K: Patient self-management: a key to effectiveness and 
efficiency in care of chronic disease.  Public Health Rep 2004, 
119:239-243.
55. Lorig KR, Holman H: Self-management education: history, definition, 
outcomes, and mechanisms.  Ann Behav Med 2003, 26:1-7.
56. Winett RA, Tate DF, Anderson ES, Wojcik JR, Winett SG: Long-term weight 
gain prevention: a theoretically based Internet approach.  Prev Med 
2005, 41:629-641.
57. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker 
EA, Nathan DM: Reduction in the incidence of type 2 diabetes with 
lifestyle intervention or metformin.  N Engl J Med 2002, 346:393-403.
58. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-
Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, et 
al.: Prevention of type 2 diabetes mellitus by changes in lifestyle 
among subjects with impaired glucose tolerance.  N Engl J Med 2001, 
344:1343-1350.
59. Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, 
Stevens VJ, Vollmer WM, Lin PH, Svetkey LP, et al.: Effects of 
comprehensive lifestyle modification on blood pressure control: main 
results of the PREMIER clinical trial.  Jama 2003, 289:2083-2093.
60. Stevens VJ, Obarzanek E, Cook NR, Lee IM, Appel LJ, Smith D West, Milas 
NC, Mattfeldt-Beman M, Belden L, Bragg C, et al.: Long-term weight loss 
and changes in blood pressure: results of the Trials of Hypertension 
Prevention, phase II.  Ann Intern Med 2001, 134:1-11.
61. Physical Activity Guidelines for Americans   [http://www.health.gov/
paguidelines/pdf/paguide.pdf]
62. Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, Macera CA, 
Heath GW, Thompson PD, Bauman A: Physical activity and public health: 
updated recommendation for adults from the American College of 
Sports Medicine and the American Heart Association.  Circulation 2007, 
116:1081-1093.
63. Nelson ME, Rejeski WJ, Blair SN, Duncan PW, Judge JO, King AC, Macera 
CA, Castaneda-Sceppa C: Physical activity and public health in older 
adults: recommendation from the American College of Sports 
Medicine and the American Heart Association.  Med Sci Sports Exer 2007, 
39:1435-1445.
64. Hill JO, Wyatt HR: Role of physical activity in preventing and treating 
obesity.  J Appl Physiol 2005, 99:765-770.
65. Dietary Guidelines for Americans   [http://www.healthierus.gov/
dietaryguidelines]
66. Kramer MK, Kriska AM, Venditti EM, Miller RG, Brooks MM, Burke LE, 
Siminerio LM, Solano FX, Orchard TJ: Translating the Diabetes Prevention 
Program: a comprehensive model for prevention training and program 
delivery.  Am J Prev Med 2009, 37:505-511.
67. Littell RC, Milliken GA: SAS System for Mixed Models Cary, NC: SAS Institute 
Inc; 1996. 
68. Siddique J, Brown CH, Hedeker D, Duan N, Gibbons RD, Miranda J, Lavori 
PW: Missing Data in Longitudinal Trials - Part B, Analytic Issues.  
Psychiatr Ann 2008, 38:793-801.
69. Kraemer HC, Kiernan M, Essex M, Kupfer DJ: How and why criteria 
defining moderators and mediators differ between the Baron & Kenny 
and MacArthur approaches.  Health Psychol 2008, 27:S101-108.
70. Dixon JB, O'Brien PE: Changes in comorbidities and improvements in 
quality of life after LAP-BAND placement.  Am J Surg 2002, 184:51S-54S.
71. Simard B, Turcotte H, Marceau P, Biron S, Hould FS, Lebel S, Marceau S, 
Boulet LP: Asthma and sleep apnea in patients with morbid obesity: 
outcome after bariatric surgery.  Obes Surg 2004, 14:1381-1388.
72. Spivak H, Hewitt MF, Onn A, Half EE: Weight loss and improvement of 
obesity-related illness in 500 U.S. patients following laparoscopic 
adjustable gastric banding procedure.  Am J Surg 2005, 189:27-32.
73. Johnson JB, Summer W, Cutler RG, Martin B, Hyun DH, Dixit VD, Pearson 
M, Nassar M, Telljohann R, Maudsley S, et al.: Alternate day calorie 
restriction improves clinical findings and reduces markers of oxidative 
stress and inflammation in overweight adults with moderate asthma.  
Free Radic Biol Med 2007, 42:665-674.Ma et al. BMC Pulmonary Medicine 2010, 10:16
http://www.biomedcentral.com/1471-2466/10/16
Page 14 of 14
74. Eneli IU, Skybo T, Camargo CA Jr: Weight loss and asthma: a systematic 
review.  Thorax 2008, 63:671-676.
75. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, 
Pendergraft TB: Development of the asthma control test: a survey for 
assessing asthma control.  J Allergy Clin Immunol 2004, 113:59-65.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2466/10/16/prepub
doi: 10.1186/1471-2466-10-16
Cite this article as: Ma et al., The Breathe Easier through Weight Loss Life-
style (BE WELL) Intervention: A randomized controlled trial BMC Pulmonary 
Medicine 2010, 10:16